Peripheral neuropathy Board decisions

The Board granted service connection for left and right lower extremity peripheral neuropathy, finding that the conditions are related to in-service herbicide agent exposure.

The Board dismissed the appeals for service connection for a bilateral knee disability, bilateral upper and lower extremity peripheral neuropathy, lumbar spine disability, cervical spine disability, and chronic pain syndrome due to untimely notices of disagreement.

The Board denied the Veteran's claims for ratings in excess of 10 percent for left and right upper extremity ulnar neuropathy.

The veteran withdrew her appeal for an initial rating in excess of 30 percent for myasthenia gravis with left lower extremity neuropathy.

The Board granted service connection for diabetes mellitus, type II and neuropathy of the extremities due to in-service exposure to herbicide agents. The claims for a sinus disorder and facial skin disorder were remanded.

The Veteran's tinnitus is granted, while fibromyalgia, internal or external hemorrhoids, bilateral hearing loss, and neuropathy are denied.

The Board denied the veteran's claims for service connection for left and right upper extremity neuropathy, finding that there was no evidence of these conditions during service or within a reasonable time thereafter, and that they were not caused by toxic exposure or any other in-service event.

The Board granted an effective date of April 8, 2022, for the award of service connection for cervical cancer and special monthly compensation (SMC) based on loss of use of a creative organ.

The Board denied earlier effective dates for the awards of service connection and higher ratings for left and right upper extremity CTS with neuropathy.

The Board granted an increased rating of 20 percent for left ulnar neuropathy, finding that the Veteran's condition more nearly approximated moderate incomplete paralysis.

The Board denied service connection for bilateral hearing loss, left leg sciatic radiculopathy, right leg sciatic radiculopathy, and right upper extremity neuropathy due to a lack of evidence supporting current diagnoses or functional impairment.

The Board granted a 60 percent disability rating for aphonia, restored the 60 percent rating for bladder dysfunction, and denied SMC based on loss of use of the right upper extremity.

The Board denied the veteran's claims for increased ratings for type II diabetes mellitus, diabetic peripheral neuropathy of the right lower extremity, and diabetic peripheral neuropathy of the left lower extremity.

The Board granted service connection for left and right lower extremity peripheral neuropathy, finding that the conditions are related to Agent Orange exposure during the Veteran's service in Vietnam.

The Board granted service connection for bilateral lower extremity peripheral neuropathy secondary to the veteran's service-connected musculoskeletal disabilities.

The Board remands the claims for service connection for spinal stenosis, peripheral neuropathy, and bilateral lower extremity radiculopathy to correct pre-decisional duty to assist errors.

The Board denied service connection for various conditions and a TDIU, as the evidence did not support a finding that any of these disabilities were related to the Veteran's military service.

The Board denied a rating greater than 70 percent for PTSD, granted an earlier effective date of August 14, 2024, for the grant of a 70 percent rating for PTSD, and denied other claims including entitlement to an effective date prior to April 3, 2025, for the grant of a 100 percent rating evaluation for CAD.

The Veteran's claim for special monthly compensation SMC(s) was denied as there is no reasonable possibility that any of his service-connected disabilities alone prevent substantially gainful employment.

The Board granted two clothing allowances for the 2022 calendar year based on use of a right knee brace and ketoconazole shampoo 2%, but denied a clothing allowance based on use of pantoprazole.